MedDataX Logo

A Safety and Efficacy of Homeopathic Medicine Rhus Toxicodendron 30 in the Treatment of Rheumatoid Arthritis

NCT ID: NCT01905735

Last Updated: 2013-08-02

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-08-31

Study Completion Date

2014-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

the purpose of the study is to assess the safety and efficacy of commonly used Homeopathic medicine Rhustoxicodendron in 30 potency in the treatment of Rheumatoid arthritis.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

it is a multicenter phase 2 ,double blind study in patient with active Rheumatoid arthritis ,there are 2 group in the study A and B ,where group A receive Rhustoxicodendron in 30 potency the first dose will administered orally (1/2 ml)after the completion of case taking ,and repeated every 7th day for 5 month and on the other hand group B receive placebo orally in (1/2 ml) at same interval for same period .

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Rheumatoid Arthritis.

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

RA

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

placebo

1/2 ml of dispensing alcohol administered orally at every 7 day for 5 month .

Group Type PLACEBO_COMPARATOR

placebo

Intervention Type DRUG

1/2 ml of dispensing alcohol is administered every 7 day for 5 month orally.

Rhustoxicodendron 30

1/2ml Rhustoxicodendron 30 is administered orally every 7 day for 5 month.

Group Type ACTIVE_COMPARATOR

Rhustoxicodendron 30

Intervention Type DRUG

1/2ml Rhustoxicodendron 30 is administered orally every 7 day for 5 month.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Rhustoxicodendron 30

1/2ml Rhustoxicodendron 30 is administered orally every 7 day for 5 month.

Intervention Type DRUG

placebo

1/2 ml of dispensing alcohol is administered every 7 day for 5 month orally.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

poison ivy dispensing alcohol

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* those who will provide written consent to participate in the study
* patient willing to turn up for 7th day follow up
* patient who are willing and compliance to the study
* those who are between 25 to 60 years .
* patient who are willing and compliance to the study .
* ESR more then 28 mm.

Exclusion Criteria

* Participating as a subject in any other clinical research study.
* Children below the age of 25years.
* Female subject who are pregnant or planning for pregnancy within 6 month.
* History of seizures
* Breast feeding women's.
* Patient on treatment for life threatening illness like cancer aids etc.
* Patient should not have any congenital abnormality or patient should not have undergone any operative procedure as consequences of RA.
Minimum Eligible Age

25 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Healthcare Homoeo Charitable Society

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

ravinder kochhar

principal investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

ravinder kochhar, MD hom

Role: PRINCIPAL_INVESTIGATOR

Healthcare Homoeo Charitable Society

mukesh k singh, B.H.M.S

Role: STUDY_DIRECTOR

health care homoeo charitable society

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Gupta Homoeo Clinic

Delhi, National Capital Territory of Delhi, India

Site Status RECRUITING

Kochhar Clinic

Ludhiana, Punjab, India

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

India

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

seenia sharma, B.H.M.S

Role: CONTACT

Phone: 0091-7837144332

Email: [email protected]

mukesh k singh, B.H.M.S

Role: CONTACT

Phone: 0091-9463131239

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

mohit gupta, B.H.M.S

Role: primary

seenia sharma, B.H.M.S

Role: primary

mukesh k singh, B.H.M.S

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SLSGB-01

Identifier Type: -

Identifier Source: org_study_id